RT Journal Article
SR Electronic
T1 Short stature and pubertal delay in Duchenne muscular dystrophy
JF Archives of Disease in Childhood
JO Arch Dis Child
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP 101
OP 106
DO 10.1136/archdischild-2015-308654
VO 101
IS 1
A1 Wood, Claire L
A1 Straub, Volker
A1 Guglieri, Michela
A1 Bushby, Kate
A1 Cheetham, Tim
YR 2016
UL http://adc.bmj.com/content/101/1/101.abstract
AB Children with Duchenne muscular dystrophy (DMD) are shorter than their healthy peers. The introduction of corticosteroid (CS) has beneficial effects on muscle function but slows growth further and is associated with pubertal delay. In contrast to CS usage in most children and adolescents, weaning glucocorticoid is not a key objective of management in DMD. As the outlook for these young people improves, one of the main challenges is to reduce or offset the detrimental effects of CS on growth and development. This is a review of the aetiology and prevalence of short stature and delayed puberty in DMD, a summary of the treatments available and suggestions for areas of further research.